Organovo Announces Release Date for Preliminary Fiscal Fourth-Quarter 2019 Financial Results
May 17 2019 - 7:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a
conference call on Wednesday, May 22, 2019 at 5:00 p.m. Eastern
Time (ET) to discuss the Company's preliminary fiscal
fourth-quarter 2019 operating and financial highlights. In
advance of the call on May 22, 2019, Organovo will issue its fiscal
fourth-quarter 2019 earnings press release, which will be available
at http://www.organovo.com. To participate in the
teleconference, callers can dial the following numbers:
1-888-317-6003 (toll-free, U.S. callers only)
1-412-317-6061 (from outside the U.S.)
Conference Call ID: 6755803
To help ensure the conference call begins in a timely manner,
please dial in five minutes prior to the scheduled start
time. The conference call will also be simultaneously webcast
at http://www.organovo.com.
For those unable to participate in the live call, a replay of
the call will be available toll-free until May 29, 2019 at
1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers
outside the U.S.). The passcode for the replay is:
10130958. An archived replay of the webcast will also be
available at http://www.organovo.com.
About Organovo Holdings, Inc.Organovo is a
biotech platform company that has developed a leadership position
with its revolutionary ability to 3D bioprint tissues with human
functionality. The Company is pursuing multiple IND-track
programs to develop its NovoTissues® to address a number of serious
unmet medical needs in adult and pediatric populations, initially
focusing on liver disease. Organovo’s first IND-track program
for Alpha-1-antitrypsin deficiency recently received orphan drug
designation from the FDA. In order to support its plan to
initiate multiple IND-track programs, the Company is providing
access to its ExVive™ in vitro tissue disease modeling platform to
facilitate high value drug discovery and development
collaborations. Organovo’s wholly-owned subsidiary, Samsara
Sciences, provides the Company and its clients with high quality
human liver and kidney cells for research applications.
Organovo is changing the shape of life science research and
transforming medical care. Learn more at
www.organovo.com.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are
not limited to, statements regarding the potential benefits and
therapeutic uses of the Company’s therapeutic liver tissue,
including the benefits of an orphan designation; the Company’s
expectations regarding the FDA regulatory pathway and anticipated
timelines for its regulatory filings; the Company’s ability to
successfully complete additional preclinical studies; the Company’s
ability to meet market demand; and customer demand for and
acceptance of its disease modeling and other in vitro tissue
platforms. The factors that could cause the Company's actual
future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating
to the possibility that the final results of the Company's
preclinical studies may be different from the Company's studies or
interim preclinical data results and may not support further
clinical development of its therapeutic tissues; the Company may
not successfully complete the required preclinical and clinical
trials required to obtain regulatory approval for its therapeutic
tissues on a timely basis or at all; the Company may not be able to
obtain sufficient raw materials to meet market demand for its
therapeutic products; risks that competitive products may adversely
impact the market opportunity for the Company’s therapeutic tissue
candidates; the Company's ability to develop, market and sell
products and services based on its technology; the expected
benefits and efficacy of the Company's products, services and
technology; the Company’s ability to execute framework agreements
involving multi-year commitments and routine use on a timely basis,
or at all; the Company’s ability to successfully complete studies
and provide the technical information required to support market
acceptance of its products, services and technology, on a timely
basis or at all; the Company’s ability to raise sufficient funds to
support its business plan and ongoing operations; the Company's
business, research, product development, regulatory approval,
marketing and distribution plans and strategies, including its use
of third party distributors; the Company’s ability to recognize
deferred revenue; and the Company’s ability to meet its fiscal-year
2019 goals and outlook. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including its Annual Report on Form 10-K filed with the SEC on May
31, 2018. You should not place undue reliance on these
forward-looking statements, which speak only as of the date that
they were made. These cautionary statements should be considered
with any written or oral forward-looking statements that the
Company may issue in the future. Except as required by applicable
law, including the securities laws of the United States, the
Company does not intend to update any of the forward-looking
statements to conform these statements to reflect actual results,
later events or circumstances or to reflect the occurrence of
unanticipated events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2023 to Oct 2024